hepat
c
viru
hcv
infect
major
caus
chronic
liver
diseas
hepatocellular
carcinoma
yet
fulli
efficaci
treatment
miss
studi
investig
rna
interfer
rnai
specif
gene
silenc
process
mediat
small
interf
rna
sirna
duplex
antivir
strategi
hcv
synthet
sirna
design
target
conserv
sequenc
hcv
nontransl
region
ntr
locat
function
stemloop
structur
domain
hcv
intern
ribosom
entri
site
ire
crucial
initi
polyprotein
translat
sever
sirna
dramat
reduc
even
abrog
replic
select
subgenom
hcv
replicon
upon
cotransfect
human
hepatoma
cell
viral
target
sirna
upon
transfect
cell
support
autonom
replic
hcv
replicon
sirna
importantli
three
sirna
also
prove
capabl
strongli
inhibit
viru
product
cell
cultur
one
sirna
target
sequenc
highli
conserv
across
genotyp
form
critic
pseudoknot
structur
involv
translat
identifi
promis
therapeut
candid
result
indic
hcv
life
cycl
effici
block
use
properlydesign
sirna
target
function
import
highli
conserv
sequenc
hcv
ire
find
offer
novel
approach
toward
develop
iresbas
antivir
treatment
chronic
hcv
infect
hepat
c
viru
hcv
infect
major
caus
chronic
liver
diseas
hepatocellular
carcinoma
yet
fulli
efficaci
treatment
miss
studi
investig
rna
interfer
rnai
specif
gene
silenc
process
mediat
small
interf
rna
sirna
duplex
antivir
strategi
hcv
synthet
sirna
design
target
conserv
sequenc
hcv
nontransl
region
ntr
locat
function
stemloop
structur
domain
hcv
intern
ribosom
entri
site
ire
crucial
initi
polyprotein
translat
sever
sirna
dramat
reduc
even
abrog
replic
select
subgenom
hcv
replicon
upon
cotransfect
human
hepatoma
cell
viral
target
sirna
upon
transfect
cell
support
autonom
replic
hcv
replicon
sirna
importantli
three
sirna
also
prove
capabl
strongli
inhibit
viru
product
cell
cultur
one
sirna
target
sequenc
highli
conserv
across
genotyp
form
critic
pseudoknot
structur
involv
translat
identifi
promis
therapeut
candid
result
indic
hcv
life
cycl
effici
block
use
properlydesign
sirna
target
function
import
highli
conserv
sequenc
hcv
ire
find
offer
novel
approach
toward
develop
iresbas
antivir
treatment
chronic
hcv
infect
hepat
c
viru
hcv
frequent
establish
persist
infect
liver
lead
develop
chronic
hepat
potenti
liver
cirrhosi
hepatocellular
carcinoma
later
stage
chronic
hcv
infect
affect
world
popul
known
lead
factor
necessit
liver
transplant
patient
develop
countri
vaccin
avail
hcv
current
treatment
consist
administ
pegyl
interferon
ribavirin
limit
efficaci
certain
hcv
genotyp
also
produc
signific
advers
effect
review
ref
develop
altern
specif
therapi
chronic
hcv
infect
therefor
major
public
health
object
hcv
member
flavivirida
famili
contain
singlestrand
positivesens
rna
genom
encod
uniqu
precursor
polyprotein
polyprotein
process
structur
protein
nonstructur
protein
therebi
ensur
genom
replic
long
open
read
frame
flank
nontransl
region
ntr
highli
conserv
among
major
hcv
genotyp
contain
element
essenti
genom
replic
review
ref
addit
hcv
ntr
contain
highli
structur
element
name
intern
ribosom
entri
site
ire
essenti
initi
hcv
polyprotein
translat
antihcv
drug
develop
hamper
lack
effici
cell
cultur
system
support
viru
replic
unavail
access
anim
model
hcv
subgenom
rna
replicon
system
permit
assay
inhibitori
effect
antivir
candid
hcv
genom
replic
vitro
human
hepatoma
cell
recent
develop
stabl
cell
cultur
system
permit
robust
product
infecti
hcv
particl
vitro
base
strain
hcv
genotyp
facilit
investig
test
new
antivir
strategi
addit
altern
anim
model
recent
develop
seem
show
promis
evalu
candid
antivir
therapeut
anim
model
includ
transgen
mice
engraft
human
hepatocyt
well
nonendang
primat
speci
tamarin
marmoset
infect
gb
viru
b
hepatotrop
viru
close
relat
hcv
gb
viru
b
deriv
contain
function
hcv
sequenc
among
possibl
therapeut
strategi
rna
interfer
rnai
attract
path
explor
first
describ
natur
defens
mechan
plant
virus
rnai
subsequ
shown
univers
phenomenon
posttranscript
gene
silenc
initi
doublestrand
rna
lead
specif
degrad
homolog
rna
process
involv
gener
small
interf
rna
sirna
associ
multiprotein
complex
name
rna
induc
silenc
complex
use
guid
target
specif
rna
substrat
watsoncrick
basepair
sirna
introduc
directli
mammalian
cell
express
viral
vector
lead
degrad
target
sequenc
review
ref
past
year
rnai
extens
investig
altern
specif
therapi
treat
cancer
genet
diseas
infect
variou
human
pathogen
medic
import
use
vitro
vivo
model
system
review
ref
rna
virus
particular
virus
liver
tropism
hcv
ideal
candid
nucleic
acidbas
therapi
shown
effici
target
liver
review
ref
recent
variou
studi
report
variabl
inhibitori
effect
hcvspecif
synthet
sirna
small
hairpin
rna
shrna
express
viral
vector
target
sequenc
encod
variou
hcv
nonstructur
protein
well
sequenc
within
ntr
studi
reli
use
hcv
subgenom
genom
replicon
model
cell
cultur
studi
design
sirna
target
highli
conserv
sequenc
within
hcv
ntr
effici
hcvspecif
sirna
first
evalu
use
previous
describ
selfrepl
hcv
rna
allow
us
select
four
sirna
abrog
substanti
reduc
genom
replic
use
sirna
recent
describ
cell
cultur
system
support
product
genotyp
order
investig
potenc
virusspecif
sirna
inhibit
hcv
infect
select
seven
sirna
target
conserv
sequenc
pivot
domain
domain
iii
hcv
ire
within
ntr
figur
domain
particularli
import
initi
polyprotein
translat
directli
contact
ribosom
subunit
bind
translat
initi
factor
domain
iii
also
report
involv
extent
genom
replic
sirna
design
essenti
accord
previous
describ
criteria
particular
whenev
possibl
asymmetr
thermost
sirna
duplex
respect
messeng
hcv
posit
strand
rna
genom
ideal
target
sirna
harbor
strong
secondari
tertiari
structur
particular
within
ire
make
difficult
design
optim
sirna
accord
criteria
refer
earlier
hand
high
nucleotid
conserv
region
footprint
seven
hcvspecif
sirna
select
target
intern
ribosom
entri
site
ire
repres
schemat
structur
domain
iiiiv
nontransl
region
ntr
strain
hcv
genotyp
sirna
target
viral
sequenc
contain
nucleotid
chang
hcv
genotyp
sequenc
indic
b
two
replicon
use
studi
nneo
ntr
deriv
hcv
genotyp
strain
respect
schemat
repres
cell
cultur
adapt
mutat
respect
indic
arrowhead
replicon
encod
neomycin
phosphotransferas
neo
ctermin
fuse
either
human
immunodefici
viru
tat
protein
follow
footandmouth
diseas
viru
autocatalyt
cleav
protein
amino
acid
residu
core
protein
c
nneo
permit
identif
sirna
homolog
sever
hcv
genotyp
tabl
select
sirna
name
accord
nucleotid
posit
within
genom
strain
hcv
genotyp
correspond
first
nucleotid
target
sirna
antisens
strand
tabl
sirna
target
end
domain
iii
end
domain
iv
involv
pseudoknot
locat
upstream
initi
codon
figur
sequenc
sirna
except
match
hcv
genotyp
sequenc
present
subgenom
replicon
use
first
part
studi
figur
two
sirna
synthes
sequenc
homolog
genotyp
respect
target
genotyp
ntr
form
g
u
wobbl
basepair
posit
sirna
antisens
strand
wherea
form
c
mismatch
genotyp
replicon
figur
g
u
noncanon
basepair
known
nondisrupt
doublestrand
rna
structur
g
u
wobbl
basepair
c
mismatch
present
certain
posit
sirna
recent
report
well
toler
sirnamedi
gene
silenc
therefor
proceed
analyz
effect
homolog
heterolog
replicon
target
final
nonspecif
neg
control
experi
use
irrelev
sirna
refer
siirr
tabl
previous
use
target
sequenc
within
ntr
polioviru
strain
share
homolog
hcv
sequenc
first
evalu
whether
select
sirna
abl
inhibit
replic
hcv
subgenom
replicon
cell
cultur
use
previous
describ
system
allow
simpl
monitor
rna
replic
measur
enzymat
activ
name
secret
alkalin
phosphatas
seap
activ
see
materi
method
figur
hcv
sequenc
replicon
deriv
n
strain
genotyp
except
ntr
deriv
strain
genotyp
follow
coelectropor
cell
vitrotranscrib
rna
synthet
sirna
cultur
supernat
replac
daili
fresh
medium
first
day
transfect
day
seap
activ
measur
cultur
supernat
collect
first
day
seap
signal
essenti
reflect
translat
input
rna
sinc
seap
level
roughli
similar
cell
transfect
replicon
transfect
replicationdefect
rna
encod
inact
rna
polymeras
delet
activ
site
see
materi
method
rna
replic
clearli
detect
day
transfect
figur
compar
seap
level
cell
transfect
cotransfect
irrelev
sirna
siirr
significantli
affect
replic
figur
hcvspecif
sirna
show
transient
nil
effect
hcv
replic
respect
seap
express
level
day
transfect
similar
induc
transfect
alon
figur
two
sirna
therefor
util
cours
studi
sharp
contrast
sirna
prove
capabl
abolish
hcv
replic
system
yield
seap
level
low
obtain
replicationdefect
rna
presenc
sirna
seap
level
even
slightli
lower
day
transfect
obtain
result
sirnamedi
degrad
input
rna
render
unavail
translat
figur
inhibitori
effect
five
sirna
hcv
replic
shown
prolong
day
transfect
data
shown
next
monitor
doserespons
effect
five
select
sirna
use
decreas
sirna
dose
rang
ng
nmoll
per
replicon
coelectropor
experi
replicon
figur
experi
inhibit
dose
calcul
sirna
figur
sirna
prove
effici
inhibitor
hcv
rna
replic
inhibit
dose
ng
nmoll
ng
nmoll
respect
sirna
exhibit
inhibit
dose
within
ng
rang
inhibit
dose
ng
shown
substanti
higher
ng
agreement
fact
fulli
homolog
ntr
genotyp
demonstr
sequencespecif
sirna
also
found
coadministr
two
sirna
target
nonoverlap
hcv
sequenc
suboptim
dose
result
addit
inhibitori
effect
data
shown
might
prove
use
futur
studi
strategi
base
combin
sirna
sought
develop
order
prevent
occurr
escap
mutat
five
sirna
specif
target
domain
iii
hcv
ire
strongli
inhibit
subgenom
rna
replicon
replic
use
nanomolar
rang
retain
remain
part
studi
next
order
determin
whether
sirna
capabl
cure
repliconcontain
cell
investig
whether
hcv
replicon
rna
elimin
sirnatr
cell
seap
activ
basal
level
total
rna
extract
cell
cotransfect
replicon
sirna
day
transfect
analyz
hcv
rna
done
semiquantit
revers
transcriptionpolymeras
chain
reaction
rtpcr
use
hcv
primer
pair
allow
amplif
basepair
fragment
span
code
region
well
primer
pair
allow
detect
housekeep
messeng
rna
dehydrogenas
purpos
rna
quantiti
normal
figur
hcv
rna
readili
detect
similar
abund
cell
transfect
cotransfect
siirr
figur
lane
low
level
residu
transfect
rna
molecul
could
occasion
detect
experiment
condit
figur
lane
duplic
experi
use
cell
cotransfect
viral
rna
either
detect
detect
low
level
compar
result
obtain
rna
figur
lane
hcv
rna
consist
detect
cell
cotransfect
figur
lane
level
lower
cell
cotransfect
siirr
result
correl
well
inhibit
level
report
seap
activ
confirm
hcv
rna
replic
strongli
inhibit
abolish
cell
treat
three
effici
sirna
order
work
cell
cultur
system
mimick
establish
persist
infect
analyz
inhibitori
capac
sirna
cell
stabli
contain
continu
replic
replicon
ongo
replic
replicon
cell
reflect
seap
level
tenfold
higher
transient
experi
hcv
replicon
electropor
two
microgram
sirna
electropor
cell
effect
hcv
rna
replic
determin
differ
timepoint
data
obtain
day
transfect
correspond
cumul
seap
level
secret
day
repres
figur
seap
activ
gener
hcv
replicon
presenc
either
homolog
sirna
reduc
rel
mocktransfect
cell
higher
dose
sirna
use
seap
activ
reduc
data
shown
sirnamedi
inhibitori
effect
dramat
cotransfect
experi
probabl
due
part
limit
transfect
effici
data
shown
therebi
permit
ongo
rna
replic
cell
receiv
sirna
transfect
cultur
addit
viral
rna
undergo
replic
within
replic
complex
may
less
access
transfect
viral
rna
sirna
nonetheless
demonstr
strong
dosedepend
inhibitori
potenc
hcv
domain
iiispecif
sirna
cell
support
continu
hcv
rna
replic
next
address
question
efficaci
sirna
inhibit
hcv
genom
replic
cell
place
select
pressur
examin
whether
hcv
escap
specif
sirna
treatment
experi
use
hcv
repliconfre
subclon
cell
either
nneo
replicon
contrast
nneo
replicon
see
figur
ref
contain
ntr
deriv
n
strain
genotyp
encod
neomycin
phosphotransferas
gene
first
cistron
cell
coelectropor
either
nneo
replicon
sirna
place
select
pressur
cell
clone
count
day
transfect
data
two
three
experi
carri
replicon
pool
sirna
homolog
replicon
mean
data
shown
figur
mean
resist
cell
clone
obtain
transfect
hcv
replicon
alon
data
repres
respect
clone
experi
treatment
hcvspecif
sirna
result
substanti
reduct
number
cell
clone
figur
sirna
reduc
format
cell
clone
log
wherea
reduc
cell
clone
format
log
figur
good
correl
result
obtain
seap
report
system
effici
homolog
target
heterolog
target
figur
natur
posit
mismatch
target
g
u
c
hcv
genotyp
genotyp
respect
nucleotid
sirna
antisens
strand
reason
well
toler
rnai
machineri
result
log
reduct
cell
clone
format
inhibit
howev
log
less
effici
homolog
target
experi
confirm
alreadi
describ
perfect
basepair
sirna
target
messeng
rna
requir
effect
silenc
look
potenti
emerg
sirna
escap
mutant
sever
cell
clone
obtain
singl
treatment
sirna
isol
independ
amplifi
ntr
hcv
replicon
rna
recov
cell
clone
sirna
reversetranscrib
pcramplifi
result
pcr
product
subject
sequenc
nucleotid
substitut
found
within
vicin
sirnatarget
region
hcv
replicon
rna
data
suggest
either
singl
sirna
treatment
may
suffici
select
hcv
replicon
escap
mutant
system
replic
compet
toler
nucleotid
variat
genom
region
sought
determin
whether
sirna
shown
effici
inhibit
replic
hcv
subgenom
replicon
transient
select
pressur
also
capabl
effici
block
viru
infect
cell
cultur
util
strain
hcv
genotyp
shown
infect
cell
line
produc
infecti
particl
vitro
infecti
system
therefor
recapitul
entir
hcv
life
cycl
sequenc
perfectli
homolog
ntr
sequenc
genotyp
strain
contrast
shown
hybrid
ntr
c
mismatch
third
posit
sirna
antisens
strand
see
figur
mismatch
end
antisens
strand
expect
hamper
rnai
reason
also
use
engin
chimer
viru
contain
ntr
corecod
sequenc
deriv
genotyp
within
backbon
genom
figur
contrast
hcvspecif
sirna
consider
reduc
number
cell
infect
either
chimer
viru
figur
similarli
effici
inhibit
infect
chimer
viru
figur
left
weak
effect
infect
figur
right
consist
exist
mismatch
genotyp
ntr
see
figur
interestingli
sirna
also
appear
higher
inhibitori
effect
infect
chimer
viru
figur
left
figur
right
spite
perfect
homolog
ntr
sequenc
virus
hypothes
differenti
effect
might
link
delay
replic
kinet
chimer
viru
compar
delgrang
pillez
l
cocquerel
g
paranhosbaccala
j
dubuisson
et
al
unpublish
result
phenotyp
may
impact
targetsirna
ratio
earli
timepoint
follow
infect
effect
three
sirna
virus
also
monitor
western
blot
analysi
express
infect
cell
figur
data
obtain
confirm
effici
sirna
caus
complet
inhibit
express
cell
infect
either
c
order
verifi
whether
viru
product
sirnatr
cell
reduc
accordingli
viral
particl
titrat
supernat
cell
transfect
sirna
infect
either
chimer
viru
realtim
quantit
rtpcr
genom
equival
figur
determin
infecti
focusform
unit
tabl
sirna
quantif
viru
product
sirnatr
cultur
figur
tabl
good
agreement
core
intracellular
express
level
figur
b
particular
supernat
hcvinfect
cell
exhibit
reduct
genom
equivalentsml
titer
reduct
focusform
unitsml
infecti
titer
compar
mocktreat
hcvinfect
cell
taken
togeth
data
demonstr
hcv
ntrspecif
sirna
capabl
strongli
inhibit
viru
product
cell
cultur
explor
rnai
potenti
new
therapeut
approach
hcv
infect
one
reason
choic
target
domain
iii
hcv
ntr
domain
iii
contain
wellconserv
nucleotid
sequenc
across
hcv
genotyp
tabl
high
degre
conserv
seen
sequenc
may
requir
preserv
viru
function
sinc
ntr
domain
control
initi
polyprotein
translat
modul
rna
replic
recent
nuclear
magnet
reson
electron
cryomicroscopi
studi
domain
iii
help
identifi
structurefunct
relationship
variou
subdomain
domain
iii
result
studi
suggest
subdomain
iiiac
iiid
well
subdomain
iiif
form
pseudoknot
structur
figur
directli
contact
subunit
bodi
act
synergist
proper
posit
aug
codon
present
studi
hybrid
subdomain
iiid
essenti
hybrid
iiif
pseudoknot
therefor
target
region
essenti
ire
structur
integr
function
three
sirna
prove
abl
low
dose
nanomolar
rang
substanti
reduc
even
abolish
hcv
subgenom
rna
replic
measur
report
seap
activ
cell
clone
format
figur
result
elimin
hcv
replicon
treat
cell
figur
importantli
also
demonstr
sirna
particularli
consider
limit
hcv
infect
cell
cultur
use
two
hcv
strain
propag
cell
strain
hcv
genotyp
ii
chimer
deriv
carri
ntr
core
sequenc
hcv
genotyp
delgrang
pillez
l
cocquerel
g
paranhosbaccala
j
dubuisson
et
al
unpublish
result
data
contrast
obtain
other
conclud
domain
ii
iii
hcv
ntr
rel
resist
sirna
reduc
access
domain
given
associ
differ
protein
factor
involv
translat
data
indic
region
involv
complex
secondari
tertiari
structur
disregard
target
rnai
data
also
underscor
import
sirna
design
contrast
two
sirna
test
present
studi
target
domain
iiic
iiie
respect
exhibit
poor
transient
inhibitori
effect
hcv
rna
replic
figur
interestingli
two
studi
report
sirna
sequenc
ident
show
rel
discrep
effect
cell
support
autonom
replic
hcv
subgenom
replicon
conflict
result
may
explain
differ
strategi
use
sirna
synthesi
andor
deliveri
addit
sensit
replicon
system
use
may
impact
sirna
effici
report
observ
differ
sirna
effici
transient
replic
system
viral
target
rna
sirna
cointroduc
cell
figur
ii
stabl
replic
system
sirna
introduc
cell
support
ongo
replic
viral
target
whether
deal
subgenom
replicon
figur
genomelength
infecti
rna
figur
tabl
two
microgram
sirna
inhibit
viral
rna
replic
stabl
subgenom
replicon
system
effici
cotransfect
experi
compar
figur
addit
caus
elimin
viral
rna
upon
cotransfect
subgenom
replicon
figur
wherea
substanti
reduc
abolish
product
viru
particl
figur
tabl
spite
fact
molar
ratio
sirna
target
hcv
rna
higher
cell
stabli
contain
hcv
replicon
infect
viru
cell
cotransfect
replicon
sirna
anoth
studi
high
dose
pmol
sirna
prove
necessari
order
strongli
inhibit
hcv
rna
replic
subgenom
repliconcontain
cell
specul
viral
rna
templat
engag
replicas
complex
nascent
rna
probabl
access
rnai
machineri
transfect
viral
rna
data
also
explain
part
fact
proport
cell
cultur
infect
support
ongo
viral
rna
replic
receiv
sirna
given
effici
electropor
cell
data
shown
specif
hcv
sirna
demontr
studi
doseeffect
respons
figur
well
use
target
replicon
ntr
two
hcv
genotyp
figur
target
ntr
genotyp
viru
strain
figur
tabl
use
heterolog
target
sirna
exhibit
noncanon
wobbl
basepair
mismatch
end
posit
sirna
antisens
strand
respect
figur
replicon
perfect
basepair
prefer
maximum
rnai
efficaci
g
u
wobbl
c
mismatch
toler
figur
consist
fact
wobbl
basepair
known
well
toler
doublestrand
rna
helic
provid
stabil
similar
watsoncrick
basepair
agreement
data
wobbl
basepair
especi
locat
end
sirna
antisens
strand
recent
suggest
disrupt
effect
rnai
surprisingli
also
consist
data
report
c
mismatch
deleteri
doublestrand
rna
structur
contrast
toler
mismatch
sirna
viral
target
rna
found
c
mismatch
end
sirna
antisens
strand
strongli
reduc
inhibitori
effect
infect
cell
cultur
figur
tabl
consist
rnai
mechan
taken
togeth
data
provid
strong
evid
involv
spuriou
interferonmedi
mechan
inhibit
suppress
viral
replic
observ
sequenc
rna
virus
hcv
known
evolv
continu
result
product
mani
quasispeci
high
error
rate
rnadepend
rna
polymeras
proofread
activ
properti
allow
rna
virus
escap
rapidli
select
pressur
antivir
treatment
sequenc
chang
compat
viru
function
hold
true
antiproteas
antipolymeras
compound
current
develop
hcv
treatment
howev
observ
singl
sirna
treatment
emerg
escap
mutat
within
sirnatarget
genom
region
rna
extract
sever
cell
clone
studi
sirnaresist
viral
mutant
harbor
singl
nucleotid
substitut
delet
within
vicin
sirnatarget
sequenc
report
emerg
cell
express
constitut
shrna
case
human
immunodefici
viru
infect
repeat
treatment
sirna
target
polymeras
code
sequenc
case
hcv
subgenom
replicon
lack
escap
mutat
observ
studi
could
either
due
fact
singl
sirna
use
treatment
fact
sirna
target
highli
conserv
function
import
genom
sequenc
substitut
would
compat
translationrepl
compet
addit
studi
need
order
determin
hypothes
hold
true
point
view
evalu
potenc
sirnabas
antivir
strategi
erad
persist
infect
recent
shown
sirna
may
use
cure
vitro
persist
infect
caus
rna
virus
polioviru
lymphocyt
choriomening
viru
assay
therapeut
strategi
anim
model
synthet
sirna
need
chemic
stabil
formul
effici
deliv
success
util
stabil
lipidencapsul
sirna
report
mous
model
hepat
b
viru
replic
addit
organ
celltyp
specif
deliveri
sirna
achiev
sirna
bind
cholesterol
antibodi
direct
cell
surfac
antigen
synthet
shrna
also
show
prolong
inhibitori
effect
murin
liver
sirna
demonstr
upon
codeliveri
shrna
sirna
target
domain
iv
hcv
ire
plasmid
dna
encod
report
protein
place
translat
control
hcv
ire
altern
optim
sirna
deliveri
may
reli
use
viral
vector
allow
continu
synthesi
shrna
cell
therebi
lead
sustain
rnai
crucial
howev
control
intracellular
shrna
product
level
sinc
recent
report
constant
high
express
shrna
liver
could
lethal
mous
model
nevertherless
control
dose
sirna
express
shrna
alreadi
shown
effici
safe
sever
anim
model
viral
infect
includ
mous
model
hepat
b
viru
infect
rhesu
macaqu
model
sever
acut
respiratori
syndromeassoci
coronaviru
infect
mous
model
west
nile
viru
japanes
enceph
viru
infect
present
studi
identifi
promis
antihcv
sirna
lesser
extent
target
highli
conserv
sequenc
domain
iii
ntr
effici
silenc
hcv
infect
cell
cultur
becom
possibl
monitor
effect
sirna
vivo
use
tamarinmarmoset
primat
model
infect
chimer
gb
viru
bcontain
hcv
domain
iii
hcv
ire
previous
describ
revis
manuscript
kanda
et
al
report
deliveri
hcv
ntrspecif
shrna
hepatoma
cell
line
infect
hcv
result
reduct
viral
product
hepatoma
cell
line
huap
deriv
hepatocarcinoma
cell
line
cultur
dulbecco
modifi
eagl
medium
invitrogen
cergypontois
franc
supplement
fetal
calf
serum
uml
penicillin
streptomycin
cell
stabli
express
seap
control
human
immunodefici
viru
long
termin
repeat
promot
cultur
presenc
blasticidin
invivogen
toulous
franc
cell
support
autonom
replic
hcv
replicon
cultur
presenc
blasticidin
mgml
geneticin
invitrogen
cergypontois
franc
genotyp
chimer
viru
stock
gener
transfect
huap
cell
correspond
vitro
transcrib
genom
rna
plasmid
contain
genomelength
complementari
dna
cdna
isol
hcv
genotyp
genbank
access
ref
gener
provid
wakita
plasmid
deriv
substitut
nucleotid
ntr
well
capsid
code
sequenc
correspond
sequenc
strain
genotyp
delgrang
pillez
l
cocquerel
g
paranhosbaccala
j
dubuisson
et
al
describ
elsewher
plasmid
linear
xbai
treat
mung
bean
nucleas
prior
vitro
transcript
use
megascript
kit
ambion
courtaboeuf
franc
huap
cell
electropor
vitro
transcrib
rna
previous
describ
supernat
collect
day
transfect
use
reinfect
huap
cell
supernat
collect
day
infect
use
viru
stock
store
design
synthesi
sirna
sirna
target
hcv
ire
design
use
previous
describ
criteria
sequenc
sensestrand
sirna
select
shown
tabl
sirna
refer
nucleotid
posit
within
genom
strain
hcv
genotyp
correspond
first
nucleotid
target
sirna
antisens
strand
synthes
sequenc
homolog
hcv
subtyp
ie
contain
u
c
residu
posit
sirna
antisens
strand
irrelev
sirna
name
siirr
target
ntr
sabin
strain
polioviru
type
use
neg
control
studi
sequenc
sirna
compar
known
gene
use
basic
local
align
search
tool
within
genbank
databas
signific
homolog
gene
found
two
strand
sirna
chemic
synthes
institut
pasteur
plateform
anneal
final
concentr
previous
describ
qualiti
quantiti
hybrid
sirna
analyz
electrophoresi
nondenatur
agaros
gel
hcv
subgenom
replicon
vitro
transcript
two
dicistron
subgenom
hcv
replicon
encod
select
report
gene
neomycin
phosphotransferas
neo
use
studi
see
figur
replicon
cdna
kindli
provid
sm
lemon
insert
downstream
rna
polymeras
promot
previous
describ
refer
replicon
nneo
respect
studi
nneo
carri
cell
cultur
adapt
mutat
respect
replicon
cdna
deriv
cdna
n
strain
genotyp
hcv
except
ntr
sequenc
deriv
strain
hcv
genotyp
rna
encod
human
immunodefici
viru
tat
protein
fuse
proteas
footandmouth
diseas
viru
follow
neo
upon
transfect
cell
replicon
express
drive
synthesi
secret
seap
cdna
bear
delet
includ
three
codon
gdd
activ
site
rna
polymeras
within
backbon
nneo
refer
use
replicationdefici
rna
plasmid
dna
linear
xbai
prior
vitro
transcript
use
megascript
kit
dna
templat
remov
treatment
turbo
dnase
ambion
courtaboeuf
franc
rna
purifi
phenolchloroform
extract
precipit
ethanol
qualiti
quantiti
replicon
rna
analyz
electrophoresi
nondenatur
agaros
gel
optic
densiti
measur
cell
transfect
cell
electropor
replicon
rna
coelectropor
replicon
rna
variou
dose
sirna
mmgap
width
cuvett
appli
one
puls
v
easyject
plu
equibio
kent
uk
cell
resuspend
complet
medium
immedi
puls
seed
variou
concentr
cell
support
autonom
replic
replicon
similarli
transfect
electropor
sirna
transfect
cell
seed
plate
supernat
collect
day
electropor
replac
fresh
medium
seap
activ
measur
supernat
aliquot
phosphalight
system
appli
biosystemstropix
courtaboeuf
franc
use
luminesc
substrat
accord
manufactur
recommend
luminesc
signal
read
second
use
lumat
lb
luminomet
berthold
technolog
thoiri
franc
select
cell
clone
variabl
fraction
transfect
cell
seed
mmdiamet
dish
supplement
transfect
cell
adjust
final
number
cell
cell
per
dish
twentyfour
fortyeight
hour
follow
transfect
cell
place
select
pressur
mgml
geneticin
invitrogen
cergypontois
franc
week
medium
replac
twice
week
cell
clone
support
viral
rna
replic
fix
stain
crystal
violet
solut
select
expand
select
pressur
viral
rna
sequenc
viral
rna
sequenc
total
rna
extract
expand
sirnaresist
clone
trizol
reagent
invitrogen
cergypontois
franc
viral
rna
revers
transcrib
amplifi
hcv
specif
primer
design
gener
pcr
product
span
nucleotid
use
superscript
onestep
rtpcr
kit
platinum
taq
invitrogen
cergypontois
franc
sequenc
reaction
carri
unclon
rtpcr
product
use
big
dye
termin
version
kit
appli
biosystem
courtaboeuf
franc
analyz
abi
capillari
dna
sequenc
appli
biosystem
courtaboeuf
franc
en
transfect
cell
seed
plate
duplic
well
per
transfect
cultur
day
trypsin
passag
dilut
new
plate
day
transfect
total
rna
extract
